Advertisement
ALXO vs MDGL
Which Stock Would AI Choose? ALX Oncology Holdings (ALXO) vs. Madrigal Pharmaceuticals (MDGL) Stock Comparison
Key Takeaways
- Two very different biotech stages: ALXO is a clinical-stage, pre-revenue developer; MDGL is commercial-stage with a blockbuster product already on the market.
- Momentum contrasts sharply: MDGL has generated triple-digit sales growth but sits in a year-to-date pullback, while ALXO trades near multi-year lows on binary clinical risk.
- Revenue gap is vast: MDGL reported quarterly product revenue in the hundreds of millions; ALXO records no product revenue and relies on its balance sheet.
- Catalyst profiles differ: MDGL awaits confirmatory outcomes data, while ALXO hinges on early-to-mid-stage trial readouts.
- Analyst sentiment is bullish on both: Each carries a "Strong Buy" consensus, though for different reasons and with very different risk profiles.
- For more detail, explore ALXO Major News and ALXO Today's Price Move, along with MDGL Major News and MDGL Today's Price Move.
- To see how automated strategies are positioning across these and other names, explore Trending AI Robots.
Introduction
Comparing ALXO and MDGL is a study in contrasting biotech life cycles. ALX Oncology Holdings, a clinical-stage immuno-oncology firm, and Madrigal Pharmaceuticals, a commercial-stage leader in metabolic disease, both operate in the healthcare sector yet face fundamentally different questions of growth, risk, and valuation. This stock comparison is most relevant to investors weighing a high-risk, catalyst-driven clinical story against an established product franchise still navigating launch economics. Traders monitoring relative performance and market positioning may also find the divergence useful, as each name responds to distinct news flows, data readouts, and sentiment shifts.
ALXO Overview and Recent Performance
ALX Oncology Holdings, Inc. (ALXO) is a clinical-stage biotechnology company developing novel cancer therapies. Its lead candidate, evorpacept, is a CD47-blocking therapeutic being evaluated in combinations across HER2-positive gastric and breast cancers, while a second program, ALX2004, is an EGFR-targeted antibody-drug conjugate (ADC). In recent weeks, the shares have traded near their 52-week low, with a notable pullback over the trailing one- and three-month periods, reflecting the market's cautious view of early-stage, pre-revenue clinical risk.
Sentiment has been shaped by positive data presentations, including exploratory results showing durable responses in patients with HER2-positive disease and high CD47 expression, alongside regulatory momentum such as FDA (U.S. Food and Drug Administration) Fast Track designations. The company reported a narrower net loss in recent quarters and has strengthened its balance sheet, yet it remains dependent on mid-stage trial readouts expected over the coming quarters. Analyst coverage skews strongly positive, with a "Strong Buy" consensus and price targets well above recent trading levels, though the stock's low share price and small market capitalization underscore its speculative profile.
MDGL Overview and Recent Performance
Madrigal Pharmaceuticals, Inc. (MDGL) is a commercial-stage biopharmaceutical company focused on MASH (metabolic dysfunction-associated steatohepatitis), a form of fatty liver disease. Its product Rezdiffra (resmetirom) is the first and currently the only therapy approved for MASH, launched in 2024. Recent quarters have delivered substantial revenue growth, with trailing twelve-month net sales exceeding the blockbuster threshold and rising patient counts, reflecting strong physician adoption.
Despite this commercial momentum, the shares have pulled back on a year-to-date basis, as investors weigh the transition from rapid launch growth to a more sustainable pace, elevated operating expenses, and the cash demands of commercial and pipeline expansion. The company continues to invest in confirmatory outcomes studies, with key data readouts expected over the next couple of years, and has broadened its pipeline through licensing agreements. Consensus ratings remain positive, though the stock's premium valuation relative to near-term profitability keeps sentiment mixed.
Trending AI Robots
For traders seeking a systematic lens on names like ALXO and MDGL, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this trending selection. These bots vary widely in trading style, strategy, timeframe, performance history, and the sets of tickers they follow, allowing users to filter by criteria such as risk appetite and holding period. Whether a trader prefers short-term signal-driven moves or longer-horizon positioning, exploring the Trending AI Robots section can surface approaches aligned with current momentum and volatility profiles.
Head-to-Head Comparison
The core contrast between these two names is stage and cash flow. MDGL generates substantial, growing product revenue and is building toward eventual profitability, giving it a steadier fundamental base but exposing it to commercial execution and competitive risk in MASH. ALXO has no product revenue and depends on clinical success, creating higher binary risk but also larger potential upside if its data de-risks its pipeline.
On market positioning, MDGL benefits from first-mover status in an underpenetrated therapeutic market, yet faces investor scrutiny over spending and valuation. ALXO operates in a crowded oncology field where differentiation hinges on biomarker-driven data. Recent momentum also diverges: MDGL's slide comes despite strong fundamentals, while ALXO's weakness reflects discounted clinical uncertainty. Risk factors differ accordingly, from payer dynamics and patent timelines for one, to trial outcomes and cash runway for the other.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor MDGL on trend consistency and fundamental stability, given its established revenue base, durable demand growth, and defined catalysts. However, the verdict is probabilistic rather than definitive: ALXO presents a higher-beta, catalyst-heavy profile that could reward risk-tolerant positioning if upcoming data reinforce its clinical hypothesis. The relative attractiveness ultimately depends on an investor's tolerance for clinical risk versus commercial execution risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALXO is a Hold and MDGL is a StrongBuy.
ALXO's RSI Indicator ascends from oversold territory
The RSI Oscillator for ALXO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +11.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 212 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 46 cases where ALXO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALXO as a result. In 76 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ALXO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-1.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MDGL's RSI Indicator ascends from oversold territory
The RSI Oscillator for MDGL moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 27 of the 33 cases the stock moved higher. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 65 cases where MDGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on MDGL as a result. In 68 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for MDGL just turned positive on November 09, 2026. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in 219 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for MDGL moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MDGL entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.630) is normal, around the industry mean (3.498). P/E Ratio (-28.565) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.443) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. MDGL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ALXO | MDGL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 25 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 79 | 72 | |
P/E GROWTH RATING 1..100 | 12 | 17 | |
SEASONALITY SCORE 1..100 | n/a | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDGL's Valuation (15) in the Pharmaceuticals Other industry is significantly better than the same rating for ALXO (92) in the null industry. This means that MDGL’s stock grew significantly faster than ALXO’s over the last 12 months.
MDGL's Profit vs Risk Rating (25) in the Pharmaceuticals Other industry is significantly better than the same rating for ALXO (100) in the null industry. This means that MDGL’s stock grew significantly faster than ALXO’s over the last 12 months.
MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as ALXO (98) in the null industry. This means that MDGL’s stock grew similarly to ALXO’s over the last 12 months.
MDGL's Price Growth Rating (72) in the Pharmaceuticals Other industry is in the same range as ALXO (79) in the null industry. This means that MDGL’s stock grew similarly to ALXO’s over the last 12 months.
ALXO's P/E Growth Rating (12) in the null industry is in the same range as MDGL (17) in the Pharmaceuticals Other industry. This means that ALXO’s stock grew similarly to MDGL’s over the last 12 months.
| ALXO | MDGL | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 77% |
| Advances ODDS (%) | 3 days ago 86% | 16 days ago 75% |
| Declines ODDS (%) | 16 days ago 90% | 6 days ago 80% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 74% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALXO’s FA Score shows that 1 FA rating(s) are green while MDGL’s FA Score has 3 green FA rating(s).
- ALXO’s FA Score: 1 green, 4 red.
- MDGL’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALXO’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).
- ALXO’s TA Score: 4 bullish, 4 bearish.
- MDGL’s TA Score: 5 bullish, 3 bearish.
Price Growth
ALXO (@Biotechnology) experienced а -13.95% price change this week, while MDGL (@Biotechnology) price change was +9.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ALXO is expected to report earnings on Nov 13, 2026.
MDGL is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALXO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALXO has been loosely correlated with MDGL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALXO jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To ALXO | 1D Price Change % | ||
|---|---|---|---|---|
| ALXO | 100% | +0.90% | ||
| MDGL - ALXO | 56% Loosely correlated | +0.10% | ||
| AXON - ALXO | 45% Loosely correlated | +4.26% | ||
| AMRN - ALXO | 43% Loosely correlated | -0.34% | ||
| ARVN - ALXO | 38% Loosely correlated | -0.14% | ||
| FHTX - ALXO | 37% Loosely correlated | +10.00% | ||
More | ||||
MDGL and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.
| Ticker / NAME | Correlation To MDGL | 1D Price Change % | ||
|---|---|---|---|---|
| MDGL | 100% | +0.10% | ||
| ALXO - MDGL | 56% Loosely correlated | +0.90% | ||
| LCTX - MDGL | 43% Loosely correlated | +6.73% | ||
| CVM - MDGL | 43% Loosely correlated | -7.09% | ||
| VOR - MDGL | 42% Loosely correlated | +2.71% | ||
| CLLS - MDGL | 40% Loosely correlated | +24.32% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EMXC | 90.91 | 2.86 | +3.25% |
| iShares MSCI Emerging Markets ex China ETF (EMXC) | |||
| TSME | 45.61 | 0.36 | +0.80% |
| Thrivent Small-Mid Cap Equity ETF (TSME) | |||
| MCHS | 34.88 | 0.28 | +0.80% |
| Matthews China Innovators Active ETF (MCHS) | |||
| XFEB | 38.47 | 0.16 | +0.41% |
| FT Vest U.S. Equity Enhance & Moderate Buffer ETF - February (XFEB) | |||
| CANC | 42.29 | -0.39 | -0.91% |
| Tema Oncology ETF (CANC) | |||